Chemotherapy induced fatigue - risks and prevalence
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Chemotherapy induced fatigue - risks and prevalence. / Adnan, Ala; Brix Tange, Ulla; Honoré, Per Gustaf Hartvig.
In: Farmacja Onkologiczna, Vol. 3, No. 16, 2010, p. 23-30.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Adnan, A, Brix Tange, U & Honoré, PGH 2010, 'Chemotherapy induced fatigue - risks and prevalence', Farmacja Onkologiczna, vol. 3, no. 16, pp. 23-30.
APA
Adnan, A., Brix Tange, U., & Honoré, P. G. H. (2010). Chemotherapy induced fatigue - risks and prevalence. Farmacja Onkologiczna, 3(16), 23-30.
Vancouver
Adnan A, Brix Tange U, Honoré PGH. Chemotherapy induced fatigue - risks and prevalence. Farmacja Onkologiczna. 2010;3(16):23-30.
Author
Bibtex
@article{0b261345d8ff4ec3a89ec05d1b990619,
title = "Chemotherapy induced fatigue - risks and prevalence",
keywords = "Det tidligere Farmaceutiske Fakultet",
author = "Ala Adnan and {Brix Tange}, Ulla and Honor{\'e}, {Per Gustaf Hartvig}",
year = "2010",
language = "Dansk",
volume = "3",
pages = "23--30",
journal = "Farmacja Onkologiczna",
issn = "1897-4163",
number = "16",
}
RIS
TY - JOUR
T1 - Chemotherapy induced fatigue - risks and prevalence
AU - Adnan, Ala
AU - Brix Tange, Ulla
AU - Honoré, Per Gustaf Hartvig
PY - 2010
Y1 - 2010
KW - Det tidligere Farmaceutiske Fakultet
M3 - Tidsskriftartikel
VL - 3
SP - 23
EP - 30
JO - Farmacja Onkologiczna
JF - Farmacja Onkologiczna
SN - 1897-4163
IS - 16
ER -
ID: 34058552